<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2711234559
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Cekea
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        HYDROXYCARBAMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        63.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Sudair Pharma Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Sudair Pharma Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2272]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SUDAIR PHARMA COMPANY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XX05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The name of your medicine is Cekea. Each capsule contains Hydroxyurea (hydroxycarbamide) as the active ingredient. Hydroxyurea belongs to a group of medicines called anti-neoplastic medicines. These medicines interfere with the growth of cancer cells.</p><p>Cekea is used to treat some types of cancer such as cervical cancer and a type of leukaemia called chronic myeloid leukaemia (CML). The precise reason why you are being given Cekea is best discussed with your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Cekea Capsules:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to hydroxyurea or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have history of any blood problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe anaemia</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Cekea.</p><p>Your doctor will do regular blood tests before and whilst you are taking Cekea. You may need to control or treat the source conditions before starting treatment with Cekea.</p><p><strong>Take special care with Cekea Capsules if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have any kidney or liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are pregnant, planning to become pregnant or are breast feeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever suffered from gout</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have leg ulcers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have previously received radiotherapy or chemotherapy, or are currently taking any other medicines for cancer treatment, especially interferon therapy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have folic acid deficiency</p><p>In long term use of Cekea, secondary leukaemia has been reported. Skin cancer has also been reported in patients receiving long term hydroxyurea. You should protect your skin from the sun, regularly inspect your skin yourself and be screened by your doctor for secondary malignancies during routine follow-up visits.</p><p><strong>Other medicines and Cekea</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, especially:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antiretroviral medicines (those that inhibit or destroy a retrovirus such as HIV), e.g., didanosine, stavudine and indinavir</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Myelosuppressive medicines (including chemotherapies) and radiation therapy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some vaccines, if you recently had a vaccination or are planning to have one, tell your doctor.</p><p>Always tell your doctor about other medicines you may be taking or have recently taken including those obtained without a prescription as some medicines can affect each others actions.</p><p>It may be necessary to adjust the dose of some medicines if they are taken at the same time as Cekea.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>You should not take this medicine if you are pregnant, planning to become pregnant or are breastfeeding, unless your doctor recommends it.</p><p>When appropriate both male and female patients should discuss effective safe contraceptive measure before, during and for at least 12 months and 6 months respectively after treatment with Cekea.</p><p>For male patients only, this medicine can affect the production of sperm so you might want to discuss the possibility of conservation (by storage of sperm) with your doctor.</p><p>In addition, if you are pregnant, planning to be or breastfeeding you should not handle the capsules.</p><p><strong>Driving and using machines</strong></p><p>You may feel drowsy. You should not drive or operate any machinery unless it has been shown not to affect you and have discussed it with your doctor.</p><p><strong>Cekea contains lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.[MA1]&nbsp;</p><p>&nbsp;[MA1]This information is in the brand, Please make sure that our product contains the same excipient or otherwise please remove it</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>You may be instructed to take your medicine on either a daily basis or an irregular basis.</p><p>The recommended dose is 20-30mg of Cekea per kg of your bodyweight once a day or</p><p>80 mg per kg of your body weight once every third day.</p><p><strong>Elderly </strong>patients may be more sensitive to the effects of Cekea and may be given a lower dose.</p><p>You can take this medicine at any time of the day, before or after meals. The capsules should be swallowed whole with a glass of water. However, if you find it difficult to swallow them, the contents of the capsule can be emptied into a glass of water and taken immediately. If some of the powder floats on the surface of the water, DO NOT WORRY this is just filler from the capsule. DO NOT inhale the contents of the capsules and if you spill any on the skin wipe it immediately.</p><p>While you are being treated with Cekea it is important that you drink plenty of fluids. This will help your kidneys work well.</p><p>If you are going to have radiation therapy, this medicine will usually be started 7 days before starting radiation treatment.</p><p>You should keep taking your capsules until your doctor tells you to stop.</p><p><strong>Children</strong></p><p>There is limited experience with the use of Cekea in this age group</p><p><strong>If you take more Cekea than you should</strong></p><p>If you take too many capsules you should go to your nearest hospital Casualty Department immediately and take the medicine carton with you. The symptoms of overdose include; soreness, swelling of hands and feet and redness of skin.</p><p><strong>If you forget to take Cekea</strong></p><p>If you forget to take a dose of this medicine DO NOT take the missed dose at all. Take your next dose when it is due; DO NOT take a double dose to make up for a forgotten dose.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>If you notice any of the following symptoms, you should stop taking the capsules and tell your doctor immediately as these may be signs of an allergic reaction: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, tongue or throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching or skin rashes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unexplained fever, chills or sore throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wasting of muscles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; peeling of the skin and nails</p><p>Tell your doctor immediately if you have a high fever (&gt;39&deg;C) with stomach, lung, muscle, liver, skin or heart problems within 6 weeks of taking Cekea.</p><p>The following side effects have been seen in some people:</p><p><strong>Very common: (may affect more than 1 in 10 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood disorders (reduction in white blood cells, red blood cells and platelets)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lower back pain or pain in your side</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; black tarry stools or blood in the stools</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual bleeding or bruising</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin changes and muscle weakness (dermatomyositis) - you may experience symptoms such as muscle tenderness, muscle weakness or tiredness (especially when climbing stairs, walking or rising from a chair etc), a rash on the face, hands or other parts of the body (which in some cases maybe scaly, purple and raised).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sores on the lips or mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty or pain passing urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; absence or low amount of sperm in the semen (azoospermia or oligospermia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness, loss of energy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sickness, diarrhoea, constipation, abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin problems may occur including darkening of the skin, peeling of the skin, purple raised patches of skin and redness. There may be a worsening of existing redness or discomfort in the skin or mucous membranes if you have had radiation treatment in the past</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; temporary hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney problems</p><p><strong>Common: (may affect up to 1 in 10 people) </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unexplained shortness of breath or cough with fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness or tingling of hands or feet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems with the flow of the bile (cholestasis), the bile which is made by the liver to aid in digestion of food may not flow properly. A build up of bile can cause itchiness, yellow skin, very dark urine and very pale stools</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver (hepatitis) which cause flu-like symptoms, including tiredness, loss of appetite, fever, aching, and feeling sick/being sick, pressure or pain below the right ribs and might also include yellowing of the skin or eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness, dizziness, fits, confusion or hallucinations (seeing hearing or feeling things that are not there)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p><strong>Rare: (may affect up to 1 in 1000 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin ulceration with severe infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tumour lysis syndrome (complications of substances released from treated cancer cells entering the blood)</p><p><strong>Not known: frequency cannot be estimated from available data </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in the colour of the nails</p><p><strong>Reporting of side effects </strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your &lt;doctor, health care provider&gt; &lt;or&gt; &lt;pharmacist&gt;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not store above 30&deg;C</p><p>Store in the original package in order to protect from moisture.</p><p>Do not use this medicine after the expiry date which is stated on the blister or carton after EXP. The expiry date refers to the last day of that month.</p><p>Keep this medicine out of the sight and reach of children</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active ingredient is Hydroxyurea.</p><p>- The other ingredients are Lactose Monohydrate, Disodium Phosphate Anhydrous, Citric Acid, Colloidal Silicon Dioxide, Magnesium Stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cekea Capsules 200 mg:
White to off-white colored powder filled in size ‘3’ hard gelatin capsules with Dark green colored cap imprinted ‘SPC-08’ with white ink and Dark green colored body imprinted ’200 mg’ with white ink.

Cekea Capsules 500 mg:
White to off-white colored powder filled in size ‘0’ hard gelatin capsules with opaque light green colored cap imprinted ‘SPC-07’ with black ink and opaque pink colored body imprinted ‘500 mg’

Cekea capsules are packed in blister 10 caps x 3 blister /carton.
People who are not taking Cekea should not be exposed to it. To decrease the risk of exposure, wear disposable gloves when handling Cekea. Anyone handling Cekea should wash their hands before and after contact with the capsules. Pregnant women should not handle Cekea.
For any information about this medicine, please contact the Marketing Authorisation Holder.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder:</strong></p><p>Sudair Pharma Company (SPC)</p><p>King Fahad Road &ndash; King Fahad District, Building no. 7639</p><p>P.O. Box 12262 Riyadh, Saudi Arabia</p><p>Tel: +966-11-920001432</p><p>Fax: +966-11-4668195</p><p>Email: info@sudairpharma.com</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Sudair Pharma Company Ltd. (SPC)</p><p>Sudair &ndash; Exit 12 &ndash; Sudair Industrial Area,</p><p>Stage 1, Al-Morgan road between St. 31 &amp;</p><p>130 Riyadh 19047, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">اسم الدواء الخاص بك هو سيكيا. تحتوي كل كبسولة على المادة الفعالة هيدروكسي يوريا (هيدروكسي كارباميد). وتنتمي مادة هيدروكسي يوريا إلى مجموعة من الأدوية تسمى الأدوية المضادة للأورام. تتداخل هذه الأدوية مع نمو الخلايا السرطانية.</p><p dir="RTL">يستخدم سيكيا لعلاج بعض أنواع السرطان مثل سرطان عنق الرحم ونوع من سرطان الدم يسمى سرطان الدم النخاعي المزمن (CML). من الأفضل مناقشة السبب الدقيق الذي يجعلك تحصل على سيكيا مع طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول كبسولات سيكيا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية من هيدروكسي يوريا أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعانى من اى مشكلات في الدم سابقا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك فقر دم شديد</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول سيكيا.</p><p dir="RTL">سيقوم طبيبك بإجراء فحوص دم منتظمة قبل وأثناء تناول سيكيا. قد تحتاج إلى التحكم في المسببات الرئيسية أو معالجتها قبل بدء العلاج باستخدام سيكيا.</p><p dir="RTL"><strong>توخى عناية خاصة أثناء استخدام كبسولات سيكيا إذا:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك أي مشكلات في الكلى أو الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت حاملًا أو تخططين للحمل أو تمارسين الرضاعة الطبيعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عانيت في أي وقت مضى من النقرس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك تقرحات في الساق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلقيت سابقًا علاجًا إشعاعيًا أو علاجًا كيميائيًا، أو تتناول حاليًا أي أدوية أخرى لعلاج السرطان، وخاصة العلاج بالإنترفيرون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك نقص فى حمض الفوليك</p><p dir="RTL">تم الإبلاغ عن حدوث سرطان الدم الثانوي و سرطان الجلد أيضاً لدى المرضى الذين يتلقون سيكيا لفترات طويلة. يجب عليك حماية بشرتك من أشعة الشمس، وفحص بشرتك بنفسك بانتظام و التنسيق مع الطبيب للكشف المبكرعن الأورام الخبيثة الثانوية أثناء زيارات المتابعة الروتينية.</p><p dir="RTL"><strong>الأدوية الأخرى وسيكيا</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول مستقبلًا أي أدوية أخرى، وخاصة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للفيروسات القهقرية (تلك التي تثبط الفيروسات القهقرية أو تدمرها مثل فيروس نقص المناعة البشرية)، مثل ديدانوزين وستافودين وإندينافير</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المثبطة لنخاع العظام (بما في ذلك العلاج الكيميائي) والعلاج الإشعاعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض اللقاحات ، أخبر طبيبك إذا تلقيت مؤخرًا لقاحًا أو تخطط للحصول عليه.</p><p dir="RTL">أخبر طبيبك دائمًا عن الأدوية الأخرى التي قد تتناولها أو تناولتها مؤخرًا بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية لأن بعض الأدوية يمكن أن تؤثر على فعالية بعضها البعض.</p><p dir="RTL">قد يكون من الضروري تعديل جرعة بعض الأدوية إذا تم تناولها في نفس الوقت مع سيكيا.</p><p dir="RTL"><strong>الحمل والرضاعة والخصوبة</strong></p><p dir="RTL">يجب عدم تناول هذا الدواء إذا كنت حاملاً أو تخططين للحمل أو تمارسين الرضاعة الطبيعية، إلا إذا أوصى طبيبك بذلك.</p><p dir="RTL">عند الاقتضاء، يجب على كل من المرضى الذكور والإناث مناقشة استخدام وسائل منع الحمل الآمنة و الفعالة قبل وأثناء العلاج بسيكيا و أيضا لمدة 12 شهرًا للذكور و6 أشهر للإناث بعد الانتهاء من العلاج باستخدام سيكيا.</p><p dir="RTL">بالنسبة للمرضى الذكور فقط، يمكن أن يؤثر هذا الدواء على إنتاج الحيوانات المنوية، لذلك قد ترغب في مناقشة إمكانية الحفاظ عليها (عن طريق تخزينها) مع طبيبك.</p><p dir="RTL">بالإضافة إلى ذلك، إذا كنت حاملاً، أو تخططين للحمل أو الرضاعة، يجب ألا تمسكى بالكبسولات.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد تشعر بالنعاس. لا يجب عليك القيادة أو تشغيل أي آلات إلا إذا ثبت أن ذلك ليس له تأثيرعليك و تم مناقشة الأمر مع طبيبك.</p><p dir="RTL"><strong>يحتوي سيكيا على لاكتوز</strong></p><p dir="RTL">إذا أخبرك طبيبك أنك مصاب بالحساسية تجاه بعض السكريات، فتحدث مع طبيبك قبل تناول هذا الدواء.[A1]&nbsp;</p><p>&nbsp;[A1]This information is in the brand, Please make sure that our product contains the same excipient or otherwise please remove it</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أوصى الطبيب أو الصيدلي. استشر طبيبك أو الصيدلي إن لم تكن متأكدًا.</p><p dir="RTL">قد يُطلب منك تناول دوائك إما على أساس يومي أو على أساس غير منتظم.</p><p dir="RTL">الجرعة الموصى بها من عقار سيكيا هي 20-30 ملغم لكل كغم من وزن الجسم مرة يوميًا أو</p><p dir="RTL">80 ملغم لكل كغم من وزن الجسم مرة كل ثالث يوم.</p><p dir="RTL">قد يكون المرضى <strong>المسنون </strong>أكثر حساسية لتأثيرات سيكيا وقد يتم إعطاؤهم جرعة أقل.</p><p dir="RTL">يمكنك تناول هذا الدواء في أي وقت من اليوم، قبل الوجبات أو بعدها. يجب ابتلاع الكبسولات كاملة مع كوب من الماء. ومع ذلك، إذا وجدت صعوبة في ابتلاعها، يمكن إفراغ محتويات الكبسولة في كوب من الماء وأخذها على الفور. إذا طاف بعض المسحوق على سطح الماء، فلا تقلق، فهذا مجرد حشو من الكبسولة. لا تستنشق محتويات الكبسولات وإذا انسكبت أي منها على الجلد امسحها على الفور.</p><p dir="RTL">أثناء علاجك باستخدام سيكيا، من المهم أن تشرب الكثير من السوائل. سيساعد ذلك كليتيك على العمل جيدًا.</p><p dir="RTL">إذا كنت ستخضع للعلاج الإشعاعي، فستبدأ بتناول هذا الدواء عادة قبل 7 أيام من بدء العلاج الإشعاعي.</p><p dir="RTL">يجب أن تستمر في تناول الكبسولات حتى يوصي الطبيب بالتوقف.</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">هناك خبرة محدودة في استخدام سيكيا مع هذه الفئة العمرية</p><p dir="RTL"><strong>إذا تناولت جرعات زائدة من سيكيا</strong></p><p dir="RTL">إذا تناولت الكثير من الكبسولات، فيجب أن تذهب إلى أقرب قسم طوارئ في أي مستشفى على الفور وأن تأخذ علبة الدواء معك. تشمل أعراض الجرعة الزائدة؛ آلام في اليدين والقدمين مع تورم واحمرار في الجلد.</p><p dir="RTL"><strong>إذا نسيت تناول سيكيا</strong></p><p dir="RTL">إذا نسيت تناول جرعة من هذا الدواء، فلا تتناول الجرعة الفائتة على الإطلاق. تناول جرعتك التالية عندما يحين موعدها؛ لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL"><strong>&nbsp;إذا لاحظت أيًا من الأعراض التالية، يجب عليك التوقف عن تناول الكبسولات وإخبار طبيبك على الفور لأن هذه قد تكون علامات الإصابة بالحساسية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ الوجه أو الشفتين أو اللسان أو الحلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة أو طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى غير مبررة، قشعريرة أو التهاب الحلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضمور عضلي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقشير الجلد والأظافر</p><p dir="RTL">أخبر طبيبك على الفور إذا كنت تعاني من ارتفاع في درجة الحرارة (أعلى من 39 درجة مئوية) مع مشكلات في المعدة أو الرئة أو العضلات أو الكبد أو الجلد أو القلب في غضون 6 أسابيع من تناول سيكيا.</p><p dir="RTL">شوهدت الآثار الجانبية التالية لدى بعض الأشخاص:</p><p dir="RTL"><strong>شائع جدًا (قد تصيب أكثر من شخص واحد من بين كل 10 أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض الدم (انخفاض خلايا الدم البيضاء وخلايا الدم الحمراء والصفائح الدموية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام أسفل الظهر أو في جانبك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; براز لونه أسود أو ملاحظة دماء فيه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف أو كدمات غير اعتيادية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيّرات الجلد وضعف العضلات (التهاب الجلد والعضلات) - قد تعاني من أعراض مثل ألم العضلات أو ضعفها أو تعبها (خاصة عند صعود السلالم أو المشي أو النهوض من الكرسي وما إلى ذلك)، أو طفح جلدي على الوجه أو اليدين أو أجزاء أخرى من الجسم (والتي في بعض الحالات قد يكون متقشر ولونه أرجواني وبارز).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرحات على الشفاه أو الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة أو ألم أثناء التبول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غياب أو انخفاض كمية الحيوانات المنوية في السائل المنوي (فقد النطاف أو انخفاض عدد الحيوانات المنوية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف ا،&nbsp; فقدان الطاقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان، الإسهال، الإمساك، آلام البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحدث مشاكل الجلد بما في ذلك سواد الجلد وتقشره وملاحظة بقع أرجوانية مرتفعة من الجلد مع احمراره. قد يكون هناك تفاقم في الاحمرار أو الألم الموجود في الجلد أو الأغشية المخاطية إذا كنت قد خضعت للعلاج الإشعاعي في الماضي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر المؤقت</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكلى</p><p dir="RTL"><strong>&nbsp;شائعة (قد تصيب &nbsp;شخص واحد من بين كل 10 أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس غير مبرر أو سعال مصحوب بالحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خدر أو تنميل في اليدين أو القدمين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في تدفق الصفراء (ركود صفراوي)، قد لا تتدفق الصفراء التي يصنعها الكبد للمساعدة على هضم الطعام بشكل صحيح. يمكن أن يسبب تراكم الصفراء الحكة واصفرار الجلد، ويصبح البول داكنًا للغاية والبراز شاحبًا للغاية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد الذي يسبب أعراضًا تشبه أعراض الأنفلونزا، بما في ذلك التعب وفقدان الشهية والحمى والألم والشعور بالغثيان / المرض والضغط أو الألم أسفل الضلوع اليمنى وقد يشمل أيضًا اصفرار الجلد أو العينين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس والدوخة والنوبات والارتباك أو الهلوسة (رؤية أو سماع أو الشعور بأشياء غير موجودة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL"><strong>نادرة (قد تصيب أ شخص واحد من بين كل 1000 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرحة جلدية مع عدوى شديدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة انحلال الورم (مضاعفات المواد المنبعثة من الخلايا السرطانية المُعالَجة التي تدخل الدم)</p><p dir="RTL"><strong>غير معروف: لا يمكن تقدير معدلات حدوثها من البيانات المتاحة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيّرات في لون الأظافر</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا تفاقمت أي من الآثار الجانبية، أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة، فيرجى إخبار طبيبك أو مقدم الرعاية الصحية أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تقم بتخزين في درجة حرارة أعلى من 30 درجة مئوية</p><p dir="RTL">يجب التخزين في العلبة الأصلية للحماية من الرطوبة.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">احفظ هذا الدواء بعيدًا عن رؤية ومتناول أيدي الأطفال</p><p dir="RTL">لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- المادة الفعالة هي هيدروكسي يوريا.</p><p dir="RTL">- المكونات الأخرى هي لاكتوز مونوهيدرات، فوسفات ثنائي الصوديوم لا مائي، حمض الستريك، ثاني أكسيد السيليكون الغروي، ستيرات المغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كبسولات سيكيا 200 ملغم:</strong></p><p dir="RTL">مسحوق بلون أبيض إلى أبيض مائل للصفرة في كبسولات جيلاتينية صلبة مقاس&quot;3&quot; مع غطاء بلون أخضر داكن بطبعة &quot;SPC-08&quot;بحبر أبيض وهيكل أخضر داكن مطبوع عليه &quot;200ملغم&quot; بحبر أبيض.</p><p>&nbsp;</p><p dir="RTL"><strong>كبسولات سيكيا 500 ملغم</strong><strong>:</strong></p><p dir="RTL">مسحوق بلون أبيض إلى أبيض مائل للصفرة في كبسولات جيلاتينية صلبة مقاس &quot;0&quot;مع غطاء بلون أخضر فاتح بطبعة &quot;SPC-07&quot; بحبر أسود وهيكل وردي فاتح مطبوع عليه&quot;500 ملغم&quot;.</p><p>&nbsp;</p><p dir="RTL">كبسولات سيكيا معبأة في أشرطة من 10 كبسولات وفي كل عبوة 3 أشرطة.</p><p dir="RTL">يجب ألا يتعرض الأشخاص الذين لا يتناولون سيكيا له. لتقليل مخاطر التعرض، قم بارتداء القفازات التي تستخدم لمرة واحدة عند التعامل مع سيكيا. يجب على أي شخص يتعامل مع سيكيا أن يغسل يديه قبل وبعد ملامسة الكبسولات. ويجب على المرأة الحامل عدم التعامل مع سيكيا.</p><p dir="RTL">للحصول على أي معلومات حول هذا الدواء، يرجى الاتصال بصاحب ترخيص التسويق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب ترخيص التسويق:</strong></p><p dir="RTL">شركة سدير للأدوية (SPC)</p><p dir="RTL">طريق الملك فهد - حي الملك فهد عمارة رقم. 7639</p><p dir="RTL">صندوق بريد 12262 الرياض، المملكة العربية السعودية</p><p dir="RTL">هاتف: 920001432-11-966 +</p><p dir="RTL">فاكس: 4668195-11-966 +</p><p dir="RTL">البريد الإلكتروني: info@sudairpharma.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;الشركة المصنّعة:</strong></p><p dir="RTL">شركة سدير للأدوية (SPC)</p><p dir="RTL">سدير - مخرج 12 - منطقة سدير الصناعية،</p><p dir="RTL">المرحلة 1 طريق المرجان بين شارع 31 و</p><p dir="RTL">130 الرياض 19047، المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cekea 200 mg Capsules
Cekea 500 mg Capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cekea Capsules 200 mg
Each capsule contains:
Hydroxyurea ….……... 200 mg
Approved colors used in empty capsule shells.
Cekea Capsules 500 mg
Each capsule contains:
Hydroxyurea …….…. 500 mg
Approved colors are used in empty capsule shells.
For full excipient, refer to 6.1 section
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cekea Capsules 200 mg: 
Hard Gelatin Capsules.
Cekea Capsules 500 mg:
Hard Gelatin Capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The treatment of chronic myeloid leukaemia.</p><p>The treatment of cancer of the cervix in conjunction with radiotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p><strong>Adults</strong></p><p>Treatment regimens can be continuous or intermittent. The continuous regimen is particularly suitable for chronic myeloid leukaemia, while the intermittent regimen, with its diminished effect on the bone marrow, is more satisfactory for the management of cancer of the cervix.</p><p>Cekea should be started 7 days before concurrent irradiation therapy. If Cekea is used concomitantly with radiotherapy, adjustment of radiation dosage is not usually necessary.</p><p>An adequate trial period for determining the antineoplastic effect of Cekea is six weeks. Where there is a significant clinical response therapy may be continued indefinitely, provided that the patient is kept under adequate observation and shows no unusual or severe reactions. Therapy should be interrupted if the white cell count drops below 2.5x10<sup>9</sup> L or the platelet count below 100x10 <sup>9</sup>/L (see section 4.4).</p><p>In these cases, the counts should be reevaluated after three days and therapy resumed when the counts return to acceptable levels. Hematopoietic rebound is usually rapid. If rapid rebound has not occurred during combined Cekea and irradiation therapy, irradiation may also be interrupted. Anemia, even if severe, can be managed without interrupting Cekea therapy.</p><p>Severe gastric distress, such as nausea, vomiting, and anorexia, resulting from combined therapy may usually be controlled by interruption of Cekea administration.</p><p>Pain or discomfort from inflammation of the mucous membranes at the irradiated site (mucositis) is usually controlled by measures such as topical anesthetics and orally administered analgesics. If the reaction is severe, Cekea therapy maybe temporarily interrupted; if it is extremely severe, irradiation dosage may, in addition, be temporarily postponed.</p><p><u>Continuous therapy</u></p><p>Cekea 20-30 mg/kg should be given daily in single doses. Dosage should be based on the patient&#39;s actual or ideal weight, whichever is the less. Therapy should be monitored by repeat blood counts.</p><p><u>Intermittent therapy</u></p><p>Cekea 80 mg/kg in single doses should be given every third day. Using the intermittent regimes the likelihood of WBC depression is diminished, but if low counts are produced, 1 or more doses of Cekea should be omitted.</p><p>Concurrent use of Cekea with other myelosuppressive agents may require adjustments of dosages.</p><p><strong>Special Populations</strong></p><p><strong>Children</strong></p><p>Because of the rarity of these conditions in children, dosage regimens have not been established.</p><p><strong>Elderly</strong></p><p>Elderly patients may be more sensitive to the effects of hydroxycarbamide (hydroxyurea), and may require a lower dosage regimen.</p><p><strong>Renal Impairment</strong></p><p>Since renal excretion is a pathway of elimination, consideration should be given to decreasing the dosage of Cekea in this population.</p><p><strong>Method of administration</strong></p><p>For oral use.</p><p>NB: If the patient prefers, or is unable to swallow capsules, the contents of the capsules may be emptied into a glass of water and taken immediately. The contents of capsules should not be inhaled or allowed to come into contact with the skin or mucous membranes. Spillages must be wiped immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
-	Marked leucopenia (<2.5wbcx109/L), thrombocytopenia (<100x109/L), or severe anaemia.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Bone Marrow</u></strong></p><p>The complete status of the blood, including bone marrow examination, if indicated, as well as kidney function and liver function should be determined prior to, and repeatedly during, treatment. If bone marrow function is depressed, treatment with Cekea should not be initiated. The determination of haemoglobin level, total leukocyte counts, and platelet counts should be performed at least once a week throughout the course of hydroxycarbamide (hydroxyurea) therapy. If WBC falls below 2.5x10<sup>9</sup>/L or platelet count to &lt;100x10<sup>9</sup>/L, therapy should be interrupted. Counts should be rechecked after 3 days and treatment resumed when they rise significantly towards normal.</p><p>Cekea may produce bone marrow suppression; leukopenia is generally its first and most common manifestation. Thrombocytopenia and anaemia occur less often and are seldom seen without a preceding leukopenia. Bone marrow depression is more likely in patients who have previously received radiotherapy or cytotoxic cancer chemotherapeutic agents; Cekea should be used cautiously in such patients. The recovery from myelosuppression is rapid when Cekea therapy is interrupted.</p><p><strong><u>Anaemia</u></strong></p><p>Severe anaemia must be corrected with whole blood replacement before initiating therapy with hydroxycarbamide (hydroxyurea). If, during treatment, anaemia occurs, correct without interrupting Cekea therapy. Erythrocytic abnormalities; megaloblastic erythropoeisis, which is self-limiting, is often seen early in the course of hydroxycarbamide (hydroxyurea) therapy. The morphologic change resembles pernicious anaemia, but is not related to vitamin B12 or folic acid deficiency. The macrocytosis may mask the incidental development of folic acid deficiency; regular determinations of serum folic acid are recommended. Hydroxycarbamide (hydroxyurea) may also delay plasma iron clearance and reduce the rate of iron utilisation by erythrocytes but it does not appear to alter the red blood cell survival time.</p><p><strong><u>Irradiation</u></strong></p><p>Patients who have received irradiation therapy in the past may have an exacerbation of post irradiation erythema when Cekea is given.</p><p><strong><u>Renal </u></strong></p><p>Hydroxycarbamide (hydroxyurea) should be used with caution in patients with marked renal dysfunction.</p><p><strong><u>HIV</u></strong></p><p>Hydroxycarbamide (hydroxyurea) is not licensed for use in combination with antiretroviral agents for HIV disease and it may cause treatment failure and toxicities (in some cases fatal) in HIV patients (see section 4.5).</p><p><strong><u>Cancer</u></strong></p><p>In patients receiving long-term therapy with hydroxycarbamide (hydroxyurea) for myeloproliferative disorders, such as polycythemia vera and thrombocythemia, secondary leukaemia has been reported. It is unknown whether this leukaemogenic effect is secondary to hydroxycarbamide (hydroxyurea) or associated with the patient&#39;s underlying disease. Skin cancer has also been reported in patients receiving long-term hydroxycarbamide (hydroxyurea). Patients should be advised to protect skin from sun exposure, conduct self-inspection of the skin and be screened for secondary malignancies during routine follow-up visits.</p><p><strong><u>Vasculitis toxicities</u></strong></p><p>Cutaneous vasculitic toxicities including vasculitic ulcerations and gangrene have occurred in patients with myeloproliferative disorders during therapy with hydroxycarbamide (hydroxyurea). The risk of vasculitic toxicities is increased in patients who receive prior or concomitant interferon therapy. The digital distribution of these vasculitic ulcerations and progressive clinical behaviour of peripheral vasculitic insufficiency leading to digital infarct or gangrene were distinctly different than the typical skin ulcers generally described with Hydroxycarbamide (hydroxyurea). Due to potentially severe clinical outcomes for the cutaneous vasculitic ulcers reported in patients with myeloproliferative disease, hydroxycarbamide (hydroxyurea) should be discontinued if cutaneous vasculitic ulcerations develop and alternative cytoreductive agents should be initiated as indicated.</p><p><strong><u>Uric acid</u></strong></p><p>The possibility of an increase in serum uric acid, resulting in the development of gout or, at worst, uric acid nephropathy, should be borne in mind in patients treated with hydroxycarbamide (hydroxyurea), especially when used with other cytotoxic agents. It is therefore important to monitor uric acid levels regularly and maintain a high fluid intake during treatment.</p><p><strong><u>Lactose</u></strong></p><p>This product contains lactose, patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.[MA1]&nbsp;</p><p><strong><u>Vaccinations</u></strong></p><p>Concomitant use of Cekea with a live virus vaccine may potentiate the replication of the vaccine virus and/or may increase some of the adverse reactions of the vaccine virus because normal defence mechanisms may be suppressed by hydroxycarbamide (hydroxyurea). Vaccination with a live vaccine in a patient taking Cekea may result in severe infection. The patient&#39;s antibody response to vaccines may be decreased. The use of live vaccines should be avoided during treatment and for at least six months after treatment has finished and individual specialist advice sought (see section 4.5).</p><p>&nbsp;[MA1]This information is in the brand, Please make sure that our product contains the same excipient or otherwise please remove it</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The myelosuppressive activity may be potentiated by previous or concomitant radiotherapy or cytotoxic therapy. Fatal and non-fatal pancreatitis has occurred in HIV-infected patients during therapy with hydroxycarbamide (hydroxyurea) and didanosine, with or without stavudine. Hepatotoxicity and hepatic failure resulting in death were reported during post-marketing surveillance in HIV-infected patients treated with hydroxycarbamide (hydroxyurea) and other antiretroviral agents. Fatal hepatic events were reported most often in patients treated with the combination of hydroxycarbamide (hydroxyurea), didanosine and stavudine. This combination should be avoided. Peripheral neuropathy, which was severe in some cases, has been reported in HIV-infected patients receiving hydroxycarbamide (hydroxyurea) in combination with antiretroviral agents, including didanosine, with or without stavudine. (see section 4.4).</p><p>Studies have shown that there is an analytical interference of hydroxycarbamide (hydroxyurea) with the enzymes (urease, uricase, and lactic dehydrogenase) used in the determination of urea, uric acid and lactic acid, rendering falsely elevated results of these in patients treated with hydroxycarbamide (hydroxyurea).</p><p>Vaccinations</p><p>There is an increased risk of severe or fatal infections with the concomitant use of live vaccines. Live vaccines are not recommended in immunosuppressed patients (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Drugs which affect DNA synthesis, such as hydroxycarbamide (hydroxyurea), may be potent mutagenic agents. The physician should carefully consider this possibility before administering this drug to male or female patients who may contemplate conception. Since Cekea is a cytotoxic agent it has produced a teratogenic effect in some animal species.</p><p>In rats and dogs, high doses of hydroxycarbamide (hydroxyurea) reduced sperm production</p><p>Hydroxycarbamide (hydroxyurea) is excreted in human breast milk. Because of the potential for serious adverse reactions in nursing infants from hydroxycarbamide (hydroxyurea), a decision should be made whether to discontinue nursing or to discontinue Cekea, taking into account the importance of the drug to the mother.</p><p>Cekea can cause fetal harm when administered to a pregnant woman. Cekea should not normally be administered to patients who are pregnant, or to mothers who are breast feeding, unless the potential benefits outweigh the possible hazards.</p><p>Female patients of reproductive potential should be counselled to use effective contraception during therapy and for at least 6 months after therapy.</p><p>Azoo- or oligospermia, sometimes reversible, have been observed in men. Male patient should be informed about the possibility of sperm conservation before the start of therapy. Hydroxycarbamide (hydroxyurea) may be genotoxic.</p><p>Men under therapy are advised to use effective contraceptive measures during and at least 1 year after therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hydroxycarbamide (hydroxyurea) may cause drowsiness. Patients receiving it should not drive or operate machinery unless it has been shown not to affect physical or mental ability.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bone-marrow suppression is the major toxic effect of hydroxycarbamide (hydroxyurea)</p><p>Cutaneous vasculitic toxicities including vasculitic ulcerations and gangrene have occurred in patients with myeloproliferative disorders during therapy with hydroxycarbamide (hydroxyurea). The risk of vasculitic toxicities is increased in patients who receive prior or concomitant interferon therapy.</p><p>In some patients, hyperpigmentation, nail pigmentation, atrophy of skin and nails, scaling, violet papules and alopecia have been observed following several years of long-term daily maintenance therapy with hydroxycarbamide (hydroxyurea).</p><p>Cases of fatal and non-fatal pancreatitis and hepatotoxicity and severe peripheral neuropathy have been observed in HIV patients when hydroxycarbamide (hydroxyurea) was administered with antiretroviral agents, in particular didanosine plus stavudine. Patients treated with hydroxycarbamide (hydroxyurea) in combination with didanosine, stavudine and indinavir showed a median decline in CD4 cells of approximately 100/mm<sup>3</sup> (see sections 4.4 and 4.5).</p><p>Adverse reactions observed with combined hydroxycarbamide (hydroxyurea) and irradiation therapy were similar to those reported with the use of hydroxycarbamide (hydroxyurea) alone, primarily bone marrow depression (leukopenia and anaemia) and gastric irritation. Nearly all patients receiving an adequate course of combined hydroxycarbamide (hydroxyurea) and irradiation therapy will develop leukopenia. Decreased platelet counts (&lt;100,000/mm<sup>3</sup>) have occurred rarely and usually in the presence of marked leukopenia. Hydroxycarbamide (hydroxyurea) may potentiate some adverse reactions usually seen with irradiation alone, such as gastric distress and mucositis.</p><p><strong>Hypersensitivity</strong></p><p>Drug induced fever</p><p>High fever (&gt;39&deg;C) requiring hospitalisation in some cases has been reported concurrently with gastrointestinal, pulmonary, muscloskeletal, hepatobiliary, dermatoloigical or cardiovascular manifestations. Onset typically occurred within 6 weeks of initiation and resolved promptly after discontinuation of hydroxycarbamide (hydroxyurea). Upon readministration fever re-occurred within 24 hours.</p><p>The list is presented by system organ class, MedDRA preferred term, and frequency using the following frequency categories: very common (&ge;1/10), common (&ge;1/100, &lt; 1/10), uncommon (&ge;1/1000, &lt;1/100), rare (&ge;1/10000, &lt;1/1000),very rare (&lt; 1/10000), and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>MedDRA Term</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and Infestations</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Gangrene</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms Benign and Malignant (including cysts and polyps)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Skin cancer</p></td></tr><tr><td style="vertical-align:top"><p>Blood and Lymphatic System Disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Bone marrow failure, CD4 lymphocytes decreased, leukopenia, thrombocytopenia, platelet count decreased, anaemia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Metabolism and Nutrition Disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Anorexia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Tumour lysis syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric Disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hallucination, disorientation</p></td></tr><tr><td style="vertical-align:top"><p>Nervous System Disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Convulsion, dizziness, peripheral neuropathy<sup>1</sup>, somnolence, headache</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, Thoracic, and Mediastinal Disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Pulmonary fibrosis, pulmonary oedema, lung infiltration, dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal Disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Pancreatitis<sup>1</sup>, nausea, vomiting, diarrhoea, stomatitis, constipation, mucositis, stomach discomfort, dyspepsia, abdominal pain, melaena</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary Disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hepatotoxicity<sup>1</sup>, hepatic enzyme increased, cholestasis, hepatitis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and Subcutaneous Tissue Disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Cutaneous vasculitis, dermatomyositis, alopecia, rash maculo-papular, rash papular, skin exfoliation, skin atrophy, skin ulcer, erythema, skin hyperpigmentation, nail disorder</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Nail pigmentation</p></td></tr><tr><td style="vertical-align:top"><p>Renal and Urinary Disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Dysuria, blood creatinine increased, blood urea increased, blood uric acid increased</p></td></tr><tr><td style="vertical-align:top"><p>General Disorders and Administration Site Conditions</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Pyrexia, asthenia, chills, malaise</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>azoospermia, oligospermia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>1</sup> Fatal and non-fatal pancreatitis and hepatotoxicity and severe peripheral neuropathy have been reported in HIV-infected patients who received hydroxycarbamide (hydroxyurea) in combination with antiretroviral agents, in particular didanosineplus stavudine</p></td></tr></tbody></table><p><u>To reports any side effect(s):</u></p><p><strong>Saudi Arabia:</strong></p><p><img src="data:image/png;base64,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" alt="" width="595" height="100" vspace="0" hspace="0" border="0" style="width:595px;height:100px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>&nbsp;</p><p><strong>Other GCC States:</strong></p><p><strong><img src="data:image/png;base64,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" alt="" width="800" height="42" vspace="0" hspace="0" border="0" style="width:800px;height:42px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Immediate treatment consists of gastric lavage, followed by supportive therapy for the cardiorespiratory systems if required. In the long term, careful monitoring of the haemopoietic system is essential and, if necessary, blood should be transfused.</p><p>Acute mucocutaneous toxicity has been reported in patients receiving hydroxycarbamide (hydroxyurea) at a dosage several times greater than that recommended. Soreness, violet erythema, oedema on palms and foot soles followed by scaling of hands and feet, intense generalised hyperpigmentation of skin, and severe acute stomatitis were observed.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: other antineoplastic agents</p><p>ATC Code: L01XX05</p><p>Hydroxycarbamide (hydroxyurea) is an orally active antineoplastic agent. Although the mechanism of action has not yet been clearly defined, hydroxycarbamide (hydroxyurea) appears to act by interfering with synthesis of DNA.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>After oral administration hydroxycarbamide (hydroxyurea) is readily absorbed from the gastrointestinal tract. Peak plasma- concentrations are reached in 2 hours; by 24 hours the serum concentrations are virtually zero. Approximately 80% of an oral or intravenous dose of 7 to 30 mg/kg may be recovered from the urine within 12 hours. Hydroxycarbamide (hydroxyurea) crosses the blood-brain barrier. Hydroxycarbamide (hydroxyurea) is well distributed throughout the body.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hydroxycarbamide (hydroxyurea) is unequivocally genotoxic and a presumed transpecies carcinogen which implies a carcinogenic risk to humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose Monohydrate</p><p>Disodium Phosphate Anhydrous</p><p>Citric Acid</p><p>Colloidal Silicon Dioxide</p><p>Magnesium Stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cekea Capsules 200 mg:</p><p>White to off-white colored powder filled in size &lsquo;3&rsquo; hard gelatin capsules with Dark green colored cap imprinted &lsquo;SPC-08&rsquo; with white ink and Dark green colored body imprinted &rsquo;200 mg&rsquo; with white ink.</p><p>Cekea Capsules 500 mg:</p><p>White to off-white colored powder filled in size &lsquo;0&rsquo; hard gelatin capsules with opaque light green colored cap imprinted &lsquo;SPC-07&rsquo; with black ink and opaque pink colored body imprinted &lsquo;500 mg&rsquo;</p><p>Cekea capsules are packed in blister. 10 caps/blister. Pack size is 3 blister/ Carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>People who are not taking Cekea should not be exposed to it. To decrease the risk of exposure, wear disposable gloves when handling Cekea. Anyone handling Cekea should wash their hands before and after contact with the capsules. If the powder is spilled, it should be immediately wiped with a damp disposable towel and discarded in a closed container, such as a plastic bag, as should the empty capsules.</p><p>Cekea should be kept away from children. Pregnant women should not handle Cekea.</p><p>To minimise the risk of dermal exposure, always wear impervious gloves when handling capsules containing Cekea. This includes all handling activities in clinical settings, pharmacies, storerooms and home healthcare settings, including during unpacking and inspection, transport within a facility, and dose preparation and administration.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sudair Pharma Company (SPC)
King Fahad Road – King Fahad District, Building no. 7639
P.O. Box 12262 Riyadh, Saudi Arabia
Tel: +966-11-920001432
Fax: +966-11-4668195
Email: info@sudairpharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>